WJA
SGMO

Williams Jones & Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Williams Jones & Associates’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,750
Closed -$50K – 396
2016
Q3 		$50K Hold
10,750
– – ﹤0.01% 389
2016
Q2 		$62K Buy
+10,750
New +$68.5K ﹤0.01% 379

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

Williams Jones & Associates's SGMO Position: Q4 2016 in Review

Williams Jones & Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2016, closing a stake of 10,750 shares — an estimated $50K sold.

Williams Jones & Associates first reported a position in SGMO in Q2 2016 and held it in 2 quarters. The position peaked at $62K in Q2 2016. 126 funds tracked by Wall St. Rank hold SGMO as of Q4 2016.

  • Williams Jones & Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2016 after selling out during the quarter.
  • Williams Jones & Associates sold 10,750 SANGAMO THERAPEUTICS INC shares in Q4 2016, an estimated $50K.
  • Williams Jones & Associates first reported a position in SANGAMO THERAPEUTICS INC in Q2 2016 and held it in 2 quarters.
  • Williams Jones & Associates's SANGAMO THERAPEUTICS INC position peaked at $62K in Q2 2016.
  • 126 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2016.

Based on Williams Jones & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.